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Abstract: The purpose of this study is to present a case of chronic sclerosing dacryoadenitis 
with high level of IgG4 in a patient diagnosed earlier with Castleman disease. A 79-year-old 
man noticed a swelling of his lower left jaw that was first seen 8 years earlier. He was diagnosed 
with Castleman disease from the histopathological examination of a biopsy of the submandibular 
gland. Since then, the size of the gland had not changed, and he had no systemic inflamma-
tory signs or symptoms. He developed diplopia a year earlier, and CT scans showed bilateral 
swelling of the lacrimal glands. He was referred to our hospital for further examinations. 
The patient underwent partial dacryoadenectomy. From the histopathological examinations, 
he was diagnosed with chronic sclerosing dacryoadenitis with high level of the serum IgG4. 
He underwent oral steroid therapy and the swollen lacrimal glands were significantly improved. 
The results suggest that there may be pathological links between IgG4-related dacryoadenitis 
and Castleman disease.
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Introduction
The pathogenesis of IgG4-related dacryoadenitis and Mikulicz’s disease is   different 
from that of Sjögren syndrome.1 However, the precise pathological definition of 
IgG4-related dacryoadenitis is still debated because there are other diseases with 
similar clinicopathological features, eg, Castleman disease.2 We report a case of 
chronic sclerosing bilateral dacryoadenitis with high level of the serum IgG4 that 
had been diagnosed with Castleman disease from the histopathological findings of a 
submandibular gland biopsy.
Case report
A 79-year-old man first noticed a swelling of his lower left jaw 8 years earlier. He was 
diagnosed with Castleman disease by histopathological examinations of a specimen 
from a swollen submandibular gland 6 years earlier. Since then, the size of the swollen 
gland had not changed and he had no symptoms or signs of systemic inflammation. He 
developed diplopia a year ago, and CT scans showed swelling of the lacrimal glands 
bilaterally, and he was referred to our hospital for further examinations.
Our examination showed that his visual acuities were slightly reduced to 0.8 OD, 
0.5 OS because of moderate cataracts. The intraocular pressures and fundus findings 
were within normal limits. His left eye was shifted to downward because of a swollen 
lacrimal gland. The results of the Schirmer test were within normal limits, but MRI Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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findings showed bilateral lacrimal gland swelling (Figure 1). 
He had no visual field defects but his eye movements were 
slightly restricted. He had no histories of systemic symptoms 
such as weight loss, skin legions, HIV infection, or recent 
vaccinations.
He underwent partial dacryoadenectomy on the right 
side because it was easier to approach than the left side. 
Histopathological examination of the lacrimal gland 
biopsy showed inflammatory cells that resembled the 
  histology of Castleman disease (Figure 2). However, some 
  histopathological findings did not agree with the histology 
of Castleman disease (Figure 2). His blood tests showed 
high levels of interleukin-6 (IL-6; 5.1 pg/mL), IL-2 receptor 
(1168 U/mL), and IgG (2790 mg/dL), which are consistent 
with Castleman disease. However, the serum level of IgG4 
was also high (695 mg/dL). Immunohistochemical analysis 
showed that the specimen was not positive for IgG4 (data not 
shown). The final diagnosis was that our patient had chronic 
sclerosing dacryoadenitis with high level of the serum IgG4 
in addition to Castleman disease.
He underwent oral steroid therapy (30 mg) and the   swollen 
lacrimal glands and his double vision were   significantly 
improved (Figure 3). His last examination 6 months after 
the steroid therapy showed that his lacrimal glands were 
not changed.
Discussion
Multicentric Castleman disease is a rare but life-threatening 
disease, and its prognosis is completely different from that 
of IgG4-related disease.2 In some patients with   Castleman 
disease, the serum IgG4 levels is increased,3–5 and the 
  histopathological findings, such as plasma cell infiltrations 
surrounding the follicles, are also similar in these diseases.6,7 
Thus, there may be pathological links between Castleman 
disease and IgG4-related diseases.
Castleman disease of the lacrimal glands is extremely 
rare, but unfortunately the serum IgG4 levels have not been 
reported in the earlier cases.7–10 Because the signs and the 
symptoms of both diseases may overlap, clinicians should 
examine the serum IgG4 levels in patients with Castleman 
disease routinely.2–5
In our case, the serum levels of both IL-6 and IgG4 
were increased, and the final diagnosis was made as chronic 
  sclerosing dacryoadenitis from the histopathological 
  examinations. Because the level of serum C-reactive protein 
(CRP) was very low, we selected steroid therapy (30 mg) to 
treat the dacryoadenitis. However, if the levels of serum IL-6 
and CRP were significantly increased, humanized anti-IL-6 
receptor antibody (tocilizumab) treatment for a multicentric 
Castleman disease would have been used because the prog-
nosis becomes poor in such an inflammatory stage of this 
disease.11
In Japan, new criteria for IgG4-positive Mikulicz’s 
disease were published by the Ministry of Health, Labour 
and Welfare in 2009. According to this report, Castleman 
disease must be ruled out before a diagnosis of IgG4-positive 
Mikulicz’s disease is made. In our case, we could not rule 
out Castleman disease as the underlying disease.
Figure 1 T2 MrI images of a patient with swollen lacrimal glands. The MrI images 
were obtained at the first visit to our hospital. The MRI findings indicate extreme 
swelling of both lacrimal glands.
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Figure 2 Histopathological findings in a specimen of the right lacrimal gland. H&E 
staining at low magnification (A ×100) and high magnification (B ×200) showing 
infiltration of plasma cells surrounding the mantle zones and a pattern of concentric 
deposits with lymphoid cells. These are pathognomic of Castleman disease. The 
infiltrated  cells  surrounding  the  mantle  zones  were  CD138  (C  ×100),  Igkappa 
(E ×100), Iglambda (F ×100), and CD79a positive (D ×100). However, compared to 
plasma cell type of Castleman disease, fibrosis in the interstitial tissue was relatively 
greater. Compared to hyaline-vascular type of Castleman disease, vascularization 
in the intrafollicular area was relatively poor. The development of mantle zones 
and the pattern of concentric deposits with infiltrating cells are not of typical of 
Castleman disease. We finally decided these tissues resemble reactive lesions rather 
than Castleman disease.Clinical Ophthalmology
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Thus, the diseases listed in the differential diagnosis of 
IgG4-positive Mikulicz’s disease have similar pathological 
features and may share in the pathogenesis. In fact, some of 
the patients with IgG4-related disease and Castleman disease 
have accompanying malignant lymphomas.6,7
In summary, we reported a case of chronic scleros-
ing dacryoadenitis with high level of the serum IgG4 in 
a patient who had been diagnosed earlier with Castleman 
disease from histopathological examinations of specimens 
biopsied from a swollen submandibular gland. In cases of 
IgG4-positive Castleman disease, oral steroid or tocilizumab 
treatment should be selected by referring to the serum IL-6 
and CRP levels. The findings in our case suggest that there 
may be pathological links between IgG4-related diseases 
and   Castleman disease.
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Figure 3 HESS charts and MRI findings before and after oral steroid administration. 
Both HESS charts and MRI findings were significantly improved after oral steroid 
administration. six months after the treatment, no recurrence was observed. The 
effect of the oral steroid treatment was consistent with the histopathological findings 
of the specimen from the lacrimal glands.